Former US FDA Heads Urge Congress: Seize Opportunity For Cosmetic, Dietary Supplement Reform
Executive Summary
Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.
You may also be interested in...
Cosmetics Reform In, Dietary Supplements Out Of US Omnibus Spending Bill
The must-pass federal spending bill includes the Modernization of Cosmetics Regulation Act, which previously appeared as a rider in US Food and Drug Administration user-fee legislation but was cut from the final iteration.
‘Rope Not Dope’ Still Convince Congress On Hemp?
Failing to maintain key non-intoxicating distinction for hemp could cost US market its future. FDA appointment of senior policy advisor for cannabis could change things.
US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation
Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.